Enroflox® 20 L.A.
Thrid-generation quinolone in long-acting vehicleInjectable Solution
Enrofloxacin 200 mg, long acting vehicle q.s.ad. 1 mL
For the treatment of infectious diseases caused by Gram-positive, Gram-negative bacteria and mycoplasma susceptible to enrofloxacine, basicaly of the respiratory tract, urinary, digestive tract, auditive conduct and skin. Bovine respiratory disease, colibacilosis, salmonellosis, neumonia, bronconeumonia, mycoplasmosis, dermatitis, mastitis-metritis-agalactia, rhinitis among others. Its vehicle provides 72 hours action.
SENASA Registry: SENASA Perú: F.03.01.N.1221